Stuart Milstein

USPTO Granted Patents = 91 (Patent Applications = 47)

CIPO Patents = 9 (Patent Applications = 24)

EPO Patents = 16 (Patent Applications = 61)

Average Co-Inventor Count = 7.1

ph-index = 12

Forward Citations = 400(Granted Patents)

Forward Citations (Not Self Cited) = 245(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Cambridge, MA (US) (2012 - 2024)
Arlington, MA (US) (2016 - 2024)

Company Filing History:

67 out of 444

Alnylam Pharmaceuticals, Inc.

patents

12 out of 96

Arrowhead Pharmaceuticals, Inc.

Arrowhead Research Corporation

patents

5. 2 out of 1,343

Regeneron Pharmaceuticals, Inc.

patents

Years Active: 2012-2025

Loading Chart...

Areas of Expertise:

iRNA Compositions

Angiopoietin-like 3

PCSK9

Hepatitis B Virus

Modified Double-stranded RNA

17ß-Hydroxysteroid Dehydrogenase

Apolipoprotein C3

TMPRSS6

Superoxide Dismutase 1

Transthyretin Expression Inhibition

Hepatitis D Virus

Organic Compositions for Disease Treatment

91 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12467051 - Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof (2025-11-11),

2. 12460206 - PCSK9 iRNA compositions and methods of use thereof (2025-11-04),

3. 12397013 - Extrahepatic delivery (2025-08-26),

4. 12385044 - Modified double-stranded RNA agents (2025-08-12),

5. 12385043 - Modified double-stranded RNA agents (2025-08-12),

6. 12378553 - Modified double-stranded RNA agents (2025-08-05),

7. 12359201 - 17ß-hydroxysteroid dehydrogenase type 13 (HSD17B13) iRNA compositions and methods of use thereof (2025-07-15),

8. 12227744 - Compositions and methods for inhibiting expression of transthyretin (2025-02-18),

9. 12173289 - Hepatitis B virus (HBV) dsRNA agent compositions and methods of use thereof (2024-12-24),

10. 12168767 - Modified double-stranded RNA agents (2024-12-17),

11. 12091661 - Organic compositions to treat HSF1-related diseases (2024-09-17),

12. 12005074 - Extrahepatic delivery (2024-06-11),

13. 11866709 - Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof (2024-01-09),

14. 11840692 - Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof (2023-12-12),

15. 11834662 - Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof (2023-12-05),

Title: The Innovative Journey of Stuart Milstein

Introduction: Stuart Milstein, a visionary inventor based in Cambridge, MA, has made significant contributions to the field of technology through his groundbreaking inventions and patents.

Latest Patents: Stuart Milstein holds several patents in the areas of artificial intelligence, renewable energy, and medical devices, showcasing his diverse range of expertise and innovative spirit.

Career Highlights: With a background in engineering and a passion for problem-solving, Stuart Milstein has led successful projects that have revolutionized industries and improved the lives of many. His commitment to innovation is evident in the numerous patents he has secured over the years.

Collaborations: Stuart Milstein has collaborated with leading research institutions, universities, and tech companies to bring his inventions to life. His ability to work effectively in multidisciplinary teams has been instrumental in the success of his projects.

Conclusion: Stuart Milstein's relentless pursuit of innovation and his dedication to pushing the boundaries of technology make him a true pioneer in the world of inventions. His impact on various industries is profound, and his legacy as an inventor continues to inspire future generations of innovators.

This text is generated by artificial intelligence and may not be accurate.